FX.co ★ AbbVie Gets Accelerated Public Reimbursement Approval Of Epkinly In Nine Canadian Provinces

AbbVie Inc. (ABBV) announced on Monday that nine provinces have granted fast-tracked public funding approval for Epkinly, a medication designed for adult patients dealing with relapsed or refractory diffuse large B-cell lymphoma. Initially, the treatment was included with specific reimbursement criteria in the provinces of Ontario and Quebec and has now received public funding across nearly all remaining provinces including Nova Scotia, British Columbia, Saskatchewan, Manitoba, and Newfoundland and Labrador. This announcement has emerged following the successful completion of negotiations under the pan-Canadian Pharmaceutical Alliance's Temporary Access Process. As of now, AbbVie's shares are trading at $188.52, reflecting a slight dip of 0.18% on the New York Stock Exchange.